PMC:7324763 / 49494-49669 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T806","span":{"begin":82,"end":90},"obj":"SP_7"},{"id":"T807","span":{"begin":153,"end":162},"obj":"UBERON:0001987"},{"id":"T808","span":{"begin":163,"end":167},"obj":"PR:000001003"},{"id":"T74629","span":{"begin":82,"end":90},"obj":"SP_7"},{"id":"T32157","span":{"begin":153,"end":162},"obj":"UBERON:0001987"},{"id":"T63952","span":{"begin":163,"end":167},"obj":"PR:000001003"}],"text":"Phase I will assess the frequency and severity of adverse events in mild, non-ICU COVID-19 patients (n = 14) following infusion of NK cells derived from placental CD34+ cells."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T604","span":{"begin":131,"end":139},"obj":"Body_part"},{"id":"T605","span":{"begin":134,"end":139},"obj":"Body_part"},{"id":"T606","span":{"begin":163,"end":174},"obj":"Body_part"},{"id":"T607","span":{"begin":169,"end":174},"obj":"Body_part"}],"attributes":[{"id":"A604","pred":"fma_id","subj":"T604","obj":"http://purl.org/sig/ont/fma/fma63147"},{"id":"A605","pred":"fma_id","subj":"T605","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A606","pred":"fma_id","subj":"T606","obj":"http://purl.org/sig/ont/fma/fma0326120"},{"id":"A607","pred":"fma_id","subj":"T607","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Phase I will assess the frequency and severity of adverse events in mild, non-ICU COVID-19 patients (n = 14) following infusion of NK cells derived from placental CD34+ cells."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T379","span":{"begin":82,"end":90},"obj":"Disease"}],"attributes":[{"id":"A379","pred":"mondo_id","subj":"T379","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Phase I will assess the frequency and severity of adverse events in mild, non-ICU COVID-19 patients (n = 14) following infusion of NK cells derived from placental CD34+ cells."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T602","span":{"begin":131,"end":139},"obj":"http://purl.obolibrary.org/obo/CL_0000623"},{"id":"T603","span":{"begin":169,"end":174},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"Phase I will assess the frequency and severity of adverse events in mild, non-ICU COVID-19 patients (n = 14) following infusion of NK cells derived from placental CD34+ cells."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1428","span":{"begin":91,"end":99},"obj":"Species"},{"id":"1433","span":{"begin":82,"end":90},"obj":"Disease"}],"attributes":[{"id":"A1428","pred":"tao:has_database_id","subj":"1428","obj":"Tax:9606"},{"id":"A1433","pred":"tao:has_database_id","subj":"1433","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Phase I will assess the frequency and severity of adverse events in mild, non-ICU COVID-19 patients (n = 14) following infusion of NK cells derived from placental CD34+ cells."}

{"project":"LitCovid-sentences","denotations":[{"id":"T312","span":{"begin":0,"end":175},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Phase I will assess the frequency and severity of adverse events in mild, non-ICU COVID-19 patients (n = 14) following infusion of NK cells derived from placental CD34+ cells."}